Comparative Pharmacology
Head-to-head clinical analysis: SUBLOCADE versus SUBUTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUBLOCADE versus SUBUTEX.
SUBLOCADE vs SUBUTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUBLOCADE contains buprenorphine, a partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. It binds to mu-opioid receptors, reducing cravings and withdrawal symptoms without producing full opioid effects, and blocks other opioids from binding due to high affinity.
Partial agonist at mu-opioid receptors; antagonist at kappa-opioid receptors. High affinity binding reduces withdrawal symptoms and blocks effects of full agonists.
300 mg subcutaneously every 4 weeks for the first 2 doses, followed by 100 mg subcutaneously every 4 weeks; maintenance dose may be increased to 300 mg every 4 weeks if tolerating lower dose.
Sublingual tablet: initial 2-4 mg, titrated to 8-16 mg daily as a single dose; maximum 24 mg per day.
None Documented
None Documented
Terminal elimination half-life is 43–50 days due to prolonged absorption from the depot; steady-state reached after 4–6 months of monthly dosing.
Terminal elimination half-life of buprenorphine ranges from 24 to 60 hours (mean ~37 hours). Clinical context: Long half-life allows for alternate-day dosing in maintenance therapy but requires careful monitoring for accumulation in renal impairment.
Primarily fecal (biliary) elimination of unchanged buprenorphine and metabolites; approximately 30% excreted in urine, mostly as conjugated metabolites.
Renal: approximately 30% of administered dose excreted unchanged in urine. Fecal: about 70% eliminated via feces, predominantly as conjugated metabolites. Biliary excretion contributes to fecal elimination.
Category C
Category C
Partial Opioid Agonist
Partial Opioid Agonist